Chicago, ILNCT06508658Now EnrollingIRB Ready

Diffuse Large B-Cell Lymphoma Clinical Trial in Chicago, IL

Access cutting-edge diffuse large b-cell lymphoma treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Genmab

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions...

Expert Care in Chicago

Access diffuse large b-cell lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related diffuse large b-cell lymphoma treatment provided free

Apply for This Chicago Location

Check if you qualify for this diffuse large b-cell lymphoma clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Diffuse Large B-Cell Lymphoma Study in Chicago

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective epcoritamab plus lenalidomide (E-Len) is compared to rituximab plus gemcitabine and oxaliplatin (R-GemOx) )in treating adult participants with relapsed or refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being

Sponsor: Genmab

Who Can Participate

Inclusion Criteria

Eastern Cooperative Oncology Group Performance status score of 0 to 2.
Histologically confirmed CD20+ Diffuse Large B-Cell Lymphoma (DLBCL) and documented in the most recent and representative pathology report, inclusive of the following according to the World Health Organization (WHO) 2022 as per the protocol.
Must have relapsed or refractory (R/R) disease and have been previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since DLBCL diagnosis.
Participant must meet at least 1 of the following criteria:
Failed prior autologous stem cell transplant (ASCT), defined as relapsed after ASCT or been refractory to high-dose therapy (HDT)-ASCT.
Not be considered a candidate for ASCT due to age, performance status, comorbidities and/or insufficient response to prior treatment, or have refused ASCT.
Be ineligible for or unable to receive chimeric antigen receptor T-cell (C

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT06508658) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Diffuse Large B-Cell Lymphoma Treatment Options in Chicago, IL

If you're searching for diffuse large b-cell lymphoma treatment options in Chicago, IL, this clinical trial (NCT06508658) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced diffuse large b-cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all diffuse large b-cell lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Chicago, IL

See all lymphoma clinical trials recruiting in Chicago — not just this study.

Browse Lymphoma Trials in Chicago

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL